Recombinant Human IGFBP-5 Protein, CF

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human IGFBP-5 Protein, CF Summary

• Details of Functionality: Measured by its ability to inhibit the biological activity of IGF-I or IGF-II on MCF‑7 human breast cancer cells. Karey, K.P. et al. (1988) Cancer Research 48:4083. The ED₅₀ for this effect is 0.5‑1.5 µg/mL in the presence of 14 ng/mL rhIGF-II.
• Source: Mouse myeloma cell line, NS0-derived human IGFBP-5 protein
  Leu21-Glu272, with an N-terminal Met
• Accession #: P24593
• N-terminal Sequence: Glu28 (Major) & Met-Leu21 (Minor)
• Protein/Peptide Type: Recombinant Proteins
• Gene: IGFBP5
• Purity: >90%, by SDS-PAGE under reducing conditions and visualized by silver stain.
• Endotoxin Note: <0.01 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Theoretical MW: 28-29 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 35-37 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in Acetonitrile and TFA.
• Purity: >90%, by SDS-PAGE under reducing conditions and visualized by silver stain.
• Reconstitution Instructions: Reconstitute at 100 μg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human IGFBP-5 Protein, CF

• IBP5IBP-5
• IGF-binding protein 5
• IGFBP5
• IGFBP-5
• insulin-like growth factor binding protein 5
• insulin-like growth factor-binding protein 5

Background

The superfamily of insulin-like growth factor (IGF) binding proteins include the six high-affinity IGF binding proteins (IGFBP) and at least four additional low-affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP). All IGFBP superfamily members are cysteine-rich proteins with conserved cysteine residues, which are clustered in the amino- and carboxy-terminal thirds of the molecule. IGFBPs modulate the biological activities of IGF proteins. Some IGFBPs may also have intrinsic bioactivity that is independent of their ability to bind IGF proteins. Post-transitional modifications of IGFBP, including glycosylation, phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins to IGF.

Human IGFBP-5 cDNA encodes a 272 amino acid (aa) residue precursor protein with a putative 20 aa residue signal peptide that is processed to generate the 252 aa residue mature protein that is post-translationally modified by O-glycosylations and serine phosphorylations. IGFBP-5 is expressed by fibroblasts, myoblasts and osteoblasts, making it the predominant IGFBP found in bone extracts. IGFBP-5 has a strong affinity for hydroxyapatite, allowing it to bind to bone cells. When bound to extracellular matrix, IGFBP-5 is protected from proteolysis and potentiates IGF activity, but when it is soluble, IGFBP-5 is cleaved to a biologically inactive 21 kDa fragment.

1. Jones, J.I. and D.R. Clemmons (1995) Endocrine Rev. 16:3.
2. Kelley, K.M. et al. (1996) Int. J. Biochem. Cell Biol. 28:619.

Publications for IGFBP-5 (875-B5)(8)

Publications using 875-B5

• G Li, J Guo, BQ Shen, D Bumbaca Ya, MX Sliwkowski, LM Crocker, JA Lacap, GD Lewis Phil Mechanisms of Acquired Resistance to Trastuzumab Emtansine in Breast Cancer Cells Mol. Cancer Ther., 2018;0(0):. 2018 [PMID: 29695635] (Bioassay, Human)
• F Sanada, J Muratsu, R Otsu, H Shimizu, N Koibuchi, K Uchida, Y Taniyama, S Yoshimura, H Rakugi, R Morishita Local Production of Activated Factor X in Atherosclerotic Plaque Induced Vascular Smooth Muscle Cell Senescence Sci Rep, 2017;7(1):17172. 2017 [PMID: 29215061] (Bioassay, Human)
• SS Mano, K Uto, M Ebara Material-induced Senescence (MIS): Fluidity Induces Senescent Type Cell Death of Lung Cancer Cells via Insulin-Like Growth Factor Binding Protein 5 Theranostics, 2017;7(19):4658-4670. 2017 [PMID: 29187894] (Bioassay, Human)
• N Han, F Zhang, G Li, X Zhang, X Lin, H Yang, L Wang, Y Cao, J Du, Z Fan Local application of IGFBP5 protein enhanced periodontal tissue regeneration via increasing the migration, cell proliferation and osteo/dentinogenic differentiation of mesenchymal stem cells in an inflammatory niche Stem Cell Res Ther, 2017;8(1):210. 2017 [PMID: 28962660] (Bioassay, Human)
• Crosley, Erin J, Dunk, Caroline, Beristain, Alexande, Christians, Julian K IGFBP-4 and -5 are expressed in first-trimester villi and differentially regulate the migration of HTR-8/SVneo cells. Reprod Biol Endocrinol, 2015;12(0):123. 2015 [PMID: 25475528] (Bioassay, Human)
• McCaig C, Duval C, Hemers E, Steele I, Pritchard DM, Przemeck S, Dimaline R, Ahmed S, Bodger K, Kerrigan DD, Wang TC, Dockray GJ, Varro A The role of matrix metalloproteinase-7 in redefining the gastric microenvironment in response to Helicobacter pylori. Gastroenterology, 2006;130(6):1754-63. 2006 [PMID: 16697739] (Bioassay, Human)
• Cortesio CL, Jiang W Mannan-binding lectin-associated serine protease 3 cleaves synthetic peptides and insulin-like growth factor-binding protein 5. Arch. Biochem. Biophys., 2006;449(1):164-70. 2006 [PMID: 16554018] (EnzAct, Human)
• Nakamura M, Miyamoto S, Maeda H, Ishii G, Hasebe T, Chiba T, Asaka M, Ochiai A Matrix metalloproteinase-7 degrades all insulin-like growth factor binding proteins and facilitates insulin-like growth factor bioavailability. Biochem. Biophys. Res. Commun., 2005;333(3):1011-6. 2005 [PMID: 15964556] (EnzAct, Human)

Bioinformatics

• Gene Symbol: IGFBP5
• Uniprot:
  • P24593()